Catalent Opens New Full-Service Clinical Supply Facility in Japan
Catalent announced the opening of its new clinical supply facility located in the Shiga prefecture of Japan, in response to increased demand for end-to-end services, including primary packaging.
The 6,000 square-meter site will provide flexible clinical supply solutions, serving both local and global biotech and pharmaceutical companies. The facility will work alongside two sites in China and one in Singapore.
Acquired from Teva-Takeda Pharmaceuticals in July 2020, the Shiga site has since undergone significant redevelopment and will also add specialized solutions for the Asia-Pacific markets including Catalent’s FastChain demand-led supply and logistics.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
